Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Anwita Biosciences

Ownership
Private
Employees
~49
Therapeutic Areas
OncologyImmunology
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
CytokinesAntibody Drug Conjugates (ADCs)Fusion Proteins

Anwita Biosciences General Information

Anwita Biosciences is advancing several Phase 1 clinical trials, including studies for Exenokine-21 and JS014, focusing on cancer and autoimmune diseases.

Contact Information

Website
https://anwitabio.com/
Primary Industry
Biotech
Corporate Office
San Carlos, California
United States

Drug Pipeline

Exenokine-21
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Anwita Biosciences's pipeline data

Book a demo

Key Partnerships

Shanghai Junshi Biosciences

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Anwita Biosciences Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Anwita Biosciences's complete valuation and funding history, request access »

Anwita Biosciences Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals